Vyjuvek (beremagene geperpavec), a gene therapy in the form of a topical gel, maintains its effectiveness for treating dystrophic epidermolysis bullosa in an open label extension study.

Patients report high satisfaction and improved quality of life, with the therapy keeping wounds closed over time.

The FDA granted approval for Vyjuvek in May 2023 after phase 3 trials demonstrated a 65% wound closure rate compared to 26% for a placebo, without significant safety concerns.

The open label study, which followed the initial trial, included 47 patients and continued to show favorable wound closure rates and high treatment satisfaction.

Vyjuvek utilizes a herpes simplex virus vector to deliver healthy genes directly to skin cells, offering a novel treatment approach for the rare genetic skin disorder.